• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Bernie Sanders Becomes First Candidate to Support Curing AIDS During Q&A with Research Foundation to Cure AIDS

Sanders: "We can and we must end the AIDS epidemic in the United States and abroad"


News provided by

Research Foundation to Cure AIDS

Oct 21, 2019, 08:00 ET

Share this article

Share this article


NEW YORK, Oct. 21, 2019 /PRNewswire/ -- Bernie Sanders is the first U.S. presidential candidate to come out in support of a cure for AIDS. Sanders' comprehensive position on curing AIDS was obtained by Research Foundation to Cure AIDS (RFTCA). So far Sanders is the first and ONLY candidate to respond to all 10 questions posed by RFTCA President, Kambiz Shekdar, Ph.D. Sanders believes the U.S. can lead the development of a global cure for AIDS.

Research Foundation to Cure AIDS is the first charitable 501(c)3 non-profit biotech venture to cure AIDS.
Research Foundation to Cure AIDS is the first charitable 501(c)3 non-profit biotech venture to cure AIDS.

"We now have all of the tools we need to end AIDS deaths and HIV transmission and develop a cure for AIDS. Now, we need the political will to do it," says Sanders.

"A cure for AIDS has been proven possible yet it remains a struggle to raise the funds needed to make it a reality. We need presidential leadership like Bernie's in order to succeed in developing a cure for all those in need," says RFTCA President Dr. Shekdar.

In response to a question about Big Pharma's corporate social responsibility, if any, in sharing the cost of developing and implementing a cure, Sanders responded, in part: "If Big Pharma does not end their greed, we will end it for them." 

When asked if Sanders would be the president to cure AIDS, his campaign responded as below:

RFTCA: President George W. Bush is credited with averting a global AIDS calamity via his administration's plan, President's Emergency Plan for AIDS Relief (PEPFAR). President Trump pledged to end the U.S. AIDS epidemic by 2030. Are you excited, ready, willing and able to rise to the opportunity and challenge of being the president to cure AIDS?

SANDERS CAMPAIGN: Yes. Bernie believes that we can and we must end the AIDS epidemic in the United States and abroad, and we can lead the world by developing a cure for AIDS. Bernie will invest significant federal resources and convene experts, advocates, scientists, and researchers to ensure this goal is met.

In addition to Sanders' support for curing AIDS, his campaign re-emphasized Sanders' support for greater access to treatment and prevention (PrEP): "As President, Bernie will fight for those living with and affected by HIV and AIDS to receive the health care — including prevention and treatment — they need as a right." 

Complete responses to all questions asked regarding curing AIDS will be published in Dr. Shekdar's column in Manhattan's West Village community newspaper, WestView News and at RFTCA.org. 

For the October 2019 edition of Dr. Shekdar's column including a questions regarding curing AIDS, see Conquering AIDS in the LGBT Presidential Town Hall: Top 10 Questions Regarding Curing AIDS. The top 10 questions only are also listed, below.

Top 10 Questions Regarding Curing AIDS

  1. If elected president, will your administration offer each of the more than 1.1 million Americans living with HIV/AIDS today any reason to hope for a cure in their lifetimes?
     
  2. Pharmaceutical manufacturers of AIDS medications have saved countless lives; they have also reaped billions in profits. What in your view is Big Pharma's corporate social responsibility, if any, to share the costs of developing and implementing a cure?
     
  3. When America set its sights on winning, American ingenuity, talent and resources have achieved near impossible goals including landing a man on the moon. As president, will you marshal our might in a new "Manhattan Project" to cure AIDS?
     
  4. Curing AIDS is as much about making room for new ideas and teams as it is about the science and technology. How will you carve out space for cellular therapies in an arena dominated by AIDS medications alone?
     
  5. An AIDS cure will offer limited national value if it is only affordable by the wealthiest 1 percent of Americans. How will you ensure that tomorrow's breakthrough therapies will reach all Americans regardless of ability to pay?
     
  6. By considering parameters for global implementation at the outset, the United States can help ensure that cellular therapies are developed such that they may be implemented from Park Avenue to the Sudan. How could you envision working with the international community to bring about a global cure for AIDS?
     
  7. Gilead Sciences, Inc., a major manufacturer of AIDS medications, is known to pay hundreds of millions of dollars to AIDS and LGBT organizations that go on to advertise its drugs on social media. What is your view of the need for transparency and accountability when it comes to the marketing of prescription drugs? 
     
  8. Heavy use of the new AIDS prophylactic drug Truvada® / PrEP manufactured by Gilead Sciences, Inc. has dropped HIV infection rates but opened the door to drug-resistant HIV/AIDS. How will you prevent the new paradigm in which people require ever-newer, stronger, more expensive and more obligatory pharmaceuticals, just to have sex?
     
  9. Even with the best medical care, doctors and insurance policies, people living with HIV/AIDS continue to suffer from side-effects, immune systems that do not fully bounce back and AIDS-related dementia. Until there is a cure, how will you help people living with HIV/AIDS achieve optimal health outcomes?
     
  10. President George W. Bush is credited with averting a global AIDS calamity via his administration's plan, President's Emergency Plan for AIDS Relief (PEPFAR). President Trump pledged to end the U.S. AIDS epidemic by 2030. Are you excited, ready, willing and able to rise to the opportunity and challenge of being the president to cure AIDS?

Questions posed by Kambiz Shekdar, Ph.D.. The author is a biologist, a biotech inventor, a gay man and the President of Research Foundation to Cure AIDS (RFTCA).

ABOUT RFTCA

RFTCA is a 501(c)3 not-for-profit organization that was founded to develop a cure for AIDS that is accessible and affordable for all. The law firm Morrison & Foerster LLP and advertising agency Havas Health Plus represent RFTCA on a pro bono basis, RFTCA's Board of Directors includes scientists affiliated with The Rockefeller University. RFTCA paid $1.00 for a perpetual worldwide license to cellular biotehnology to research, develop and commercialize a cure for AIDS. The license effectively allows RFTCA to be the first charitable biotechnology venture to cure AIDS worldwide.

PRESS CONTACT

Allison Ceraso
Communications Director
[email protected]
(212) 251-8823

SOURCE Research Foundation to Cure AIDS

Related Links

https://www.researchfoundationtocureaids.org

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.